LivingGLP1
Study S000911

Beta Cell Function in Type 2 Diabetes in Black Patients: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

ClinicalTrials.gov record

Registration

Registration
NCT07325435
Acronym
Beta
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
NONE
Status
ACTIVE_NOT_RECRUITING
Enrollment
60
Start
2024-12-21
Primary completion
2027-12-31
Lead sponsor
MaryAnn Banerji
Conditions
Type 2 Diabetes (T2DM)
Interventions
DRUG:SGLT-2 inhibitor; DRUG:GLP1-RA
Results posted
FALSE
Individual participant data sharing
NO
Secondary identifiers
OTHER_GRANT:New York Community Trust

Registered primary outcomes

  • Change in Stimulated C-peptide Index during an Oral Glucose Tolerance Test is a measure of Beta Cell Function and will be measuresd at baseline and at 16 weeks after treatment with GLP-1 Receptor Agonist or SGLT2-Inhibitor [Baseline, 16 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0024127Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM.
Ali AM, The Journal of clinical endocrinology and metabolism
2020OtherPMID 32745202DOIregistry reference BACKGROUND:32745202
R0055711From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph Anthony DeFronzo, Diabetes
2009OtherPMID 19336687DOIregistry reference BACKGROUND:19336687
R0026056Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
Mari A, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2006Randomized trialPMID 17163361DOIregistry reference BACKGROUND:17163361